FDA clearance of IND for CHM 2101
Filed with ASX · · 3 pages · English
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Entitlement Offer to raise approximately $10 million
- New data for Phase 1A CLTX CAR T brain cancer clinical trial
- Agreement with MD Anderson for Phase 1B CHM 0201 AML study
- Dosing completion in Phase 1A brain cancer clinical trial
- Chimeric to receive A$4.4 million introduction fee
Later from Chimeric Therapeutics
- 1st patient dosed in Phase 1b recurrent glioblastoma trial
- Positive in vitro data for CHM 1301 CAR NK cells
- Chimeric receives $7.36M R&D tax incentive
- ADVENT-AML Phase 1B clinical trial open to enrolment
- Placement of Entitlement Offer Shortfall
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics